Abstract:Objective To investigate the clinical effect of Thirteen-flavor Yuquan Pill in the treatment of early-stage type 2 diabetes mellitus (T2DM). Methods A total of 100 patients with early-stage T2DM were randomly divided into control group and treatment group, with 50 patients in each group. The patients in the control group were treated with oral metformin sustained-release tablets and acarbose tablets to reduce blood glucose, and those in the treatment group were treated with oral Thirteen-flavor Yuquan Pill to reduce blood glucose. The course of treatment was 3 months for both groups. The two groups were compared in terms of fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), glycosylated hemoglobin (HbA1C), fasting insulin (FINS), homeostasis model assessment β-cell function (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR), body mass index (BMI), and incidence rate of adverse events after treatment. Results Both groups had significant reductions in FPG, 2hPG, HOMA-IR, and BMI and significant increases in FINS and HOMA-β after treatment (P<0.05), and compared with the control group, the treatment group had significantly greater changes in HOMA-β and HOMA-IR after treatment (P<0.05). There was no significant difference in the incidence rate of adverse events between the two groups (P>0.05). Conclusion Thirteen-flavor Yuquan Pill has a marked clinical effect in the treatment of early-stage T2DM and can effectively reduce blood glucose, improve the function of pancreatic β cells, alleviate insulin resistance, and reduce body weight, with little adverse effect.